Lexaria Bioscience Corp. reported its financial results for the three months ended November 30, 2025. The company recorded a net loss of USD 1.6 million for the period. Research and development expenses decreased year-over-year by USD 1.3 million as Lexaria neared completion of its Phase 1b Clinical Trial (GLP-1-H24-4). Consulting fees and salaries increased by USD 31 thousand, primarily due to cost of living salary adjustments. During the quarter, the company raised USD 3.4 million in net proceeds from a Registered Direct offering completed in September 2025. Lexaria continues to focus on the optimization of its DehydraTECH formulations within its pharmaceutical division.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000080), on January 13, 2026, and is solely responsible for the information contained therein.